280 related articles for article (PubMed ID: 20922707)
21. Safety of rosuvastatin.
Shepherd J; Hunninghake DB; Stein EA; Kastelein JJ; Harris S; Pears J; Hutchinson HG
Am J Cardiol; 2004 Oct; 94(7):882-8. PubMed ID: 15464670
[TBL] [Abstract][Full Text] [Related]
22. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.
Shepherd J; Vidt DG; Miller E; Harris S; Blasetto J
Cardiology; 2007; 107(4):433-43. PubMed ID: 17363845
[TBL] [Abstract][Full Text] [Related]
23. Rhabdomyolysis and acute renal failure following hard physical activity in a patient treated with rosuvastatin.
Martínez-López D; Enríquez R; Sirvent AE; Redondo-Pachón MD; Millán I; Amorós F
Nefrologia; 2012; 32(1):127-8. PubMed ID: 22294017
[No Abstract] [Full Text] [Related]
24. Incidence of skeletal muscle disorders after statins' treatment: consequences in clinical and EMG picture.
Drobny M; Pullmann R; Odalos I; Skerenova M; Saniova B
Neuro Endocrinol Lett; 2014; 35(2):123-8. PubMed ID: 24878976
[TBL] [Abstract][Full Text] [Related]
25. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.
Alsheikh-Ali AA; Ambrose MS; Kuvin JT; Karas RH
Circulation; 2005 Jun; 111(23):3051-7. PubMed ID: 15911706
[TBL] [Abstract][Full Text] [Related]
26. Rosuvastatin and the statin wars--the way to peace.
Meyboom RH; Edwards IR
Lancet; 2004 Dec 4-10; 364(9450):1997-9. PubMed ID: 15582043
[No Abstract] [Full Text] [Related]
27. Rosuvastatin: renal disorders and rhabdomyolysis.
Prescrire Int; 2007 Apr; 16(88):68-9. PubMed ID: 17458050
[TBL] [Abstract][Full Text] [Related]
28. Characteristics and drug utilization patterns of new users of rosuvastatin and other statins in four countries.
McAfee AT; Rodríguez LA; Goettsch WG; González-Pérez A; Johansson S; Ming EE; Wallander MA; Herings RM
Minerva Cardioangiol; 2010 Dec; 58(6):611-22. PubMed ID: 21135803
[TBL] [Abstract][Full Text] [Related]
29. Myopathy caused by a combination rosuvastatin and fenofibrate.
Dedhia V; Munsi SC
J Assoc Physicians India; 2007 Feb; 55():152-3. PubMed ID: 17571748
[No Abstract] [Full Text] [Related]
30. The safety of rosuvastatin: effects on renal and hepatic function.
Guthrie RM; Martin DR
Expert Opin Drug Saf; 2007 Sep; 6(5):573-81. PubMed ID: 17877444
[TBL] [Abstract][Full Text] [Related]
31. Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment.
van Staa TP; Carr DF; O'Meara H; McCann G; Pirmohamed M
Br J Clin Pharmacol; 2014 Sep; 78(3):649-59. PubMed ID: 24602118
[TBL] [Abstract][Full Text] [Related]
32. Dangers of rosuvastatin identified before and after FDA approval.
Wolfe SM
Lancet; 2004 Jun; 363(9427):2189-90. PubMed ID: 15220045
[No Abstract] [Full Text] [Related]
33. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
34. Rosuvastatin in the management of hyperlipidemia.
Cheng JW
Clin Ther; 2004 Sep; 26(9):1368-87. PubMed ID: 15531000
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.
Kennedy SP; Barnas GP; Schmidt MJ; Glisczinski MS; Paniagua AC
J Clin Lipidol; 2011; 5(4):308-15. PubMed ID: 21784377
[TBL] [Abstract][Full Text] [Related]
36. McArdle disease with rhabdomyolysis induced by rosuvastatin: case report.
Lorenzoni PJ; Silvado CE; Scola RH; Luvizotto M; Werneck LC
Arq Neuropsiquiatr; 2007 Sep; 65(3B):834-7. PubMed ID: 17952291
[TBL] [Abstract][Full Text] [Related]
37. Individualising the risks of statins in men and women in England and Wales: population-based cohort study.
Hippisley-Cox J; Coupland C
Heart; 2010 Jun; 96(12):939-47. PubMed ID: 20489220
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.
Backes JM; Venero CV; Gibson CA; Ruisinger JF; Howard PA; Thompson PD; Moriarty PM
Ann Pharmacother; 2008 Mar; 42(3):341-6. PubMed ID: 18285559
[TBL] [Abstract][Full Text] [Related]
39. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
40. Drug safety evaluation of rosuvastatin.
Toth PP; Dayspring TD
Expert Opin Drug Saf; 2011 Nov; 10(6):969-86. PubMed ID: 21999163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
